The US Food and Drug Administration (FDA) has issued clearance for bolus insulin dosing on the t:slim X2 insulin pump with use of the t:connect mobile app, according to a press release from Tandem Diabetes Care, Inc.
The updated t:connect mobile app provides users of the t:slim X2 insulin pump with the ability to program and cancel bolus insulin requests through their compatible smartphone and is the first-ever FDA-cleared smartphone application capable of initiating insulin delivery on iOS and Android operating systems.
The new feature will be available in the United States at no additional cost to new t:slim X2 insulin pump customers and to in-warranty customers through a remote software update for the t:slim X2 insulin pump and the updated t:connect mobile app. Tandem Diabetes Care plans to introduce the mobile bolus feature update throughout the spring of 2022 in a series of limited launches, followed by an expanded launch during the summer.
The t:connect mobile app is a secure, user-friendly mobile application that displays the user’s pump information on a personal smartphone when paired with a t:slim X2 insulin pump. The mobile app also shows the previous 24 hours of glucose trends, pump status changes, and insulin therapy data, including basal and bolus deliveries and suspensions of insulin delivery. The app is equipped with pump alerts and alarms, and it securely and wirelessly uploads data into the cloud-based t:connect web application.
Not every smartphone will be able to use the bolus feature within the t:connect mobile app. More information is available at www.tandemdiabetes.com.
“With the improvements in diabetes management provided by Tandem’s Control-IQ technology, giving a meal bolus is now the most common reason a person interacts with their pump, and the ability to do so using a smartphone app offers a convenient and discrete solution,” stated John Sheridan, president and CEO of Tandem Diabetes Care, in the press release.
Tandem Diabetes Care announces FDA clearance for the t:slim X2 insulin pump to bolus using the t:connect Mobile App [press release]. San Diego, CA: Tandem Diabetes Care, Inc; February 16, 2022.
This article originally appeared on Endocrinology Advisor